CLaret Embolic Protection ANd TAVI - Trial (CLEAN-TAVI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01833052 |
Recruitment Status : Unknown
Verified May 2015 by Prof. Dr. med. A. Linke, University of Leipzig.
Recruitment status was: Active, not recruiting
First Posted : April 16, 2013
Last Update Posted : May 5, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Frequency of Cerebral Perfusion Defects After TAVI Size of Cerebral Perfusion Defects After TAVI | Device: TAVI (Medtronic CoreValve) Device: Claret-Filter | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Supportive Care |
Study Start Date : | April 2013 |
Actual Primary Completion Date : | June 2014 |
Estimated Study Completion Date : | June 2015 |
Arm | Intervention/treatment |
---|---|
Cerebral Protection Filter
Patient is treated with Cerebral protection Filter.
|
Device: TAVI (Medtronic CoreValve) Device: Claret-Filter |
No Cerebral Protection Filter
Patient is not treated with Cerebral protection Filter.
|
Device: TAVI (Medtronic CoreValve) |
- Rate and Size of Cerebral Embolism [ Time Frame: 2 days after Intervention ]Primary endpoint ist the rate and the size of cerebral embolism in postinterventional Magnetic Resonance Imaging (MRI).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject must be scheduled to undergo an endovascular aortic valve prosthesis (Medtronic CoreValve®) implant procedure with the femoral artery as the intended access site for the valve delivery system.
Exclusion Criteria:
- Patient is unsuitable for TAVI
- Prior Stroke or TIA in the last 12 month
- Carotic stenosis >70%
- Relevant stenosis of the brachiocephalic trunc or the right subclavian artery
- Expected Non-compliance for follow-ups
- Pregnancy
- Patient is already recruited for another study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01833052
Germany | |
Leipzig Herzzentrum | |
Leipzig, Germany, 04289 |
Responsible Party: | Prof. Dr. med. A. Linke, University of Leipzig |
ClinicalTrials.gov Identifier: | NCT01833052 |
Other Study ID Numbers: |
HZL-01-TAVI |
First Posted: | April 16, 2013 Key Record Dates |
Last Update Posted: | May 5, 2015 |
Last Verified: | May 2015 |